Showing 99 of 273 results

World Health Organization (WHO), UNICEF
The purpose of this document is to provide up-to-date information to support countries in making informed decisions around the appropriate yellow fever vaccine (YFV) vial presentations for routine...
Mick N. Mulders
Annex 17 Generating Consensus Sequences with Sequencher
Mick N. Mulders
Annex C 16: CDC Protocol for amplification and sequencing of measles virus MF-NCR from patient samples
World Health Organization (WHO)
The conclusions of the Global Measles and Rubella Strategic Plan 2012–2020 implementation midterm review highlighted the need to update protocols for guiding surveillance and outbreak investigation...
Chair Rebecca Fields
Rudi Eggers (WHO), Jan Grevendonk (WHO), Elicah Kandinda Kamiji (MoH Zambia), Imran Mirza (UNICEF), Abigail Shefer (US CDC)
Chair David Durrheim
Narendra Arora (INCLEN), Peter Figueroa (U of the West Indies), Jim Goodson (US CDC), Shabir Madhi (NICD, South Africa), Peter Strebel (WHO), Kim Thompson (Kids Risk)
World Health Organization (WHO)
This implementation guidance summarizes and builds on current global recommendations and programmatic considerations for establishing and/or strengthening platforms for the vaccination of health...
Edson Utazi, Dan Hogan
Communities at risk of non- and under-vaccination are often characterized by poverty, lack of access to health care and other basic services, civil/political unrest, poor sanitation practices,...
Mateusz Hasso-Agopsowicz
¿Cómo, dónde y cuándo vamos a utilizar parches de microarrays para administrar las vacunas contra el sarampión y la rubéola?
Mateusz Hasso-Agopsowicz
Les vaccins contre la rougeole et la rubéole sont sûrs et efficaces, mais la couverture équitable, en particulier pour la deuxième dose de vaccin contenant la rougeole (MCV2), est bien...
Kirstin Krudwig, Wendy Prosser
Le COVID exigeant des sessions de plus petite taille, il est plus important que jamais de réduire la taille des flacons de vaccins pour mieux les adapter à la taille des sessions. Cette...
Mateusz Hasso-Agopsowicz
Measles and rubella vaccines are safe and effective, however, achieving equitable coverage, particularly for the second dose of measles containing vaccine (MCV2) is well below the 95% target of...
WHO - Regional office for South-East Asia
The specific objectives of the review were to: i) provide a candid estimation or review of the progress towards achieving the regional goal by 2023; ii) assess the quality of implementation...
Mick N. Mulders
Annex C15. Using the RECall program
Mick N. Mulders
Comparison of measles and rubella IgM EIA kits
Mick N. Mulders
Dried blood spot (DBS) protocols
Mick N. Mulders
Invitrogen Real Time PCR Template: Rubella
Mick N. Mulders
Invitrogen Real Time PCR Template
Mick N. Mulders
Invitrogen Real Time PCR Template: Rubella with Diluted ROX
Mick N. Mulders
Real-time RT-PCR Assays for the Detection of Measles Virus (MeV) N Gene RNA and Human RNase P mRNA (a cellular reference gene) using the ABI 7500 Real-Time Thermocycler
Mick N. Mulders
Real-time RT-PCR Assays for the Detection of Rubella Virus RNA and Human RNase P mRNA using the ABI 7500 Real-time Thermocycler
Mick N. Mulders
RT-PCR protocol for rubella genotyping using nested set amplifications Enzyme kit: Qiagen One-Step RT-PCR
Mick N. Mulders
Verification for new IgM EIAs
Mick N. Mulders
Measles or rubella virus isolation and preparation of virus stocks
Mick N. Mulders
Creating a Table and Chart to Describe Genotyping Data
Mick N. Mulders
Directions for finding and using the MeaNS distinct sequence ID
Mick N. Mulders
The following protocol provides recommendations for the purification of DNA fragments from positive PCR reactions.
Mick N. Mulders
List of Abbreviation, taken from the (Manual for the Laboratory-based Surveillance of Measles, Rubella, and Congenital Rubella Syndrome
Mick N. Mulders
Annex B4a. Job Aid for Serion ELISA Classic Measles/rubella Virus IgM
Mick N. Mulders
Annex B4. Serion protocol for measles IgM ELISA
Mick N. Mulders
Annex B3. EuroImmun protocol for rubella IgM ELISA
Mick N. Mulders
Annex B2c. EuroImmun IgM ELISA Manual Calculation Worksheet with built-in calculations
Mick N. Mulders
Annex B2b. EuroImmun IgM ELISA Manual Calculation Worksheet
Mick N. Mulders
Annex B2a. Job aid for Annex B2 (and B3)
Mick N. Mulders
Annex B2. EuroImmun protocol for measles IgM ELISA
Mick N. Mulders
Annex A6. Preparation and use of FTA cards
Mick N. Mulders
Annex A3. Shipping clinical specimens
Mick N. Mulders
Annex E8. Nested RT-PCR for measles
Mick N. Mulders
Annex E7. Protocol for measles genotyping with M13 primers (CDC)
Mick N. Mulders
Annex E1. Real-time RT-PCR for measles vaccine strains
Mick N. Mulders
Annex D2. Supplemental information for optimal laboratory design
Mick N. Mulders
Annex D1. Levey–Jennings control charts
Mick N. Mulders
Annex C10. Agarose gel electrophoresis with measles and rubella synthetic positive controls
Mick N. Mulders
Annex C9. Phylogenetic analysis (MEGA v7 or X) of measles and rubella sequences assembled using Genestudio
Mick N. Mulders
Annex C8. Measles & rubella sequence assembly (editing) using GeneStudio
Mick N. Mulders
Annex C7. Rubella sequence analysis for genotyping using MEGA v5.05
Mick N. Mulders
Annex C6. Measles sequence analysis for genotyping using MEGA v6.06
Mick N. Mulders
Annex C5a. Rubella sequencing worksheet for Annex C5
Mick N. Mulders
Annex C5. Rubella sequencing protocol for genotyping (CDC)
Mick N. Mulders
Annex C4a. Measles sequencing worksheet for Annex C4
Mick N. Mulders
Annex C4. Measles sequencing protocol for genotyping (CDC)
Mick N. Mulders
Annex C3. Protocol for rubella genotyping RT-PCR, Invitrogen Superscript III (CDC)
Mick N. Mulders
Annex C01a. Worksheet for Annex C1, C2, C3.
Mick N. Mulders
Annex C2. Protocol for rubella genotyping RT-PCR, Qiagen (CDC)
Mick N. Mulders
Annex C1a. Worksheet for Annex C1 (Qiagen and Invitrogen Superscript)
Mick N. Mulders
Annex C1. Measles genotyping RT-PCR (CDC)
Mick N. Mulders
Annex B12c. RuV Real-Time Layout
Mick N. Mulders
Annex B12b. RuV Real-Time Layout (ROX dilution)
Mick N. Mulders
Annex B12a. Worksheet for Annex B12
Mick N. Mulders
Annex B12. Rubella real-time RT-PCR (NSP)
Mick N. Mulders
Annex B11c. Worksheet (triplicate wells) for Annex B11
Mick N. Mulders
Annex B11b. Plate layout (duplicate wells) for Annex B11
Mick N. Mulders
Annex B11. Measles real-time RT-PCR, N gene (CDC)
Mick N. Mulders
Annex B9. Confirmation of rubella virus in culture by IFA and ICA
Mick N. Mulders
Annex B7. Propagation and maintenance of Vero/hSLAM cell culture (CDC)
Mick N. Mulders
Annex B5. Serion protocol for rubella IgM ELISA
Mick N. Mulders
Annex B4c. Serion IgM ELISA Worksheet with built-in calculations
Mick N. Mulders
Annex B4b. Serion IgM ELISA Manual Calculation Worksheet
Mick N. Mulders
Annex A2. Measles and rubella investigation form
Mick N. Mulders
Annex A1. Measles and rubella laboratory request form
William J. Moss, Stephanie Shendale, Ann Lindstrand, Katherine L. O'Brien, Nikki Turner, Tracey Goodman, Katrina Kretsinger
This report addresses the epidemiological aspects and feasibility of measles and rubella eradication and the potential resource requirements in response to the request of the Director-General at the...
Kyla Hayford, Katherine L O'Brien, Joyce Were, E Wangeci Kagucia, Dustin G Gibson, David Obor, Benard Ochieng
Short message service (SMS) reminders coupled with a small monetary incentive conditioned on prompt vaccination have been shown to improve first-dose measles-containing vaccine (MCV1) uptake. We...
Gatien De Broucker, Sayem Ahmed, Md. Zahid Hasan, Gazi Golam Mehdi, Jorge Martin Del Campo, Md. Wazed Ali, Md. Jasim Uddin, Dagna Constenla, Bryan Patenaude
This study estimated the economic cost of treating measles in children under-5 in Bangladesh from the caregiver, government, and societal perspectives.
Dose Per Container Partnership
From January 2017 through July 2018, the DPCP conducted implementation research using quantitative and qualitative methods in Central and Luapula provinces in Zambia. The country was selected to...
World Health Organization (WHO)
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...
Xiang Li, VIMC Working Group on COVID-19 Impact on Vaccine Preventable Disease, Susy Echeverria-Londono, Niket Thakkar, Michael L. Jackson, Matthew Ferrari, Mark Jit, Kim Woodruff, Kevin McCarthy, Katy Gaythorpe, Kaja Abbas, John Huber, Caroline Trotter, Andromachi Karachaliou, Alex Perkins
The impact of COVID-19-related disruption to vaccination programs varies between infections and countries. Planning and implementation of campaigns should consider country and infection-specific...
Gatien De Broucker, Anthony Ssebagereka, Rebecca Racheal Apolot, Mutebi Aloysius, Elizabeth Ekirapa Kiracho, Bryan Patenaude, Dagna Constenla
There is very limited evidence about the economic cost of measles in low-income countries. We estimated the cost of treating measles in Uganda from a societal perspective.
Mateusz Hasso-Agopsowicz
Measles and rubella vaccines are safe and effective, however, achieving equitable coverage, particularly for the second dose of measles containing vaccine (MCV2) is well below the 95% target of...
World Health Organization (WHO)
This document was developed for public health professionals and laboratory scientists in Member States to support their decisions about conducting serosurveys in the context of achieving goals for...
World Health Organization (WHO)
This document outlines practical clinical care interventions and infection prevention and control measures required to reduce the high levels of morbidity and mortality that can occur during measles...
Dose Per Container Partnership
This executive summary details the key findings from the 5-dose MCV research in Zambia: improved coverage, reduced wastage, no cold chain constraints, and healthcare workers were more willing to open...
Dose Per Container Partnership
This case study describes the impact of changing to 5-dose measles containing vaccine in Zambia with improved coverage, lower wastage rate and no cold chain constraints.
UNICEF
This Facts Sheet informs of the availability of Measles vaccine and combined Measles-Rubella (MR) vaccine in both a 10-dose vial and a 5-dose vial presentations through (or via) UNICEF procurement....
World Health Organization (WHO)
SIA readiness assessment tool: dashboard and excel sheets
World Health Organization (WHO)
The World Health Organization (WHO) measles programmatic risk assessment tool was developed to help national programmes to identify areas not meeting measles programmatic targets, and based on the...
World Health Organization (WHO)
This ten year global plan for measles and rubella outlines the strategy that needs to be fully implemented to achieve the measles and rubella goals endorsed by the World Health Assembly. The plan...